Tvardi Therapeutics IncTVRD
Price$1.25

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $7.1M0.0% YoYTTM through 30 Jun 2026
Net Income -$18.2MTTM through 30 Jun 2026
Free Cash Flow -$26.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
EBITDA Margin-373.4%
Operating Margin-374.8%
Net Margin-255.2%

Returns

-46.9%ROE
-26.3%ROA

Balance Sheet Health

Debt / Equity0.01x
Current Ratio2.25x
Net Debt-$25Mnet cash position
Cash & Equivalents$15.8M

Quality Metrics

Altman Z-Score-12.60
Piotroski F-Score1 / 9
FCF Margin-365.3%
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'18'19'20'21'22'23'24
FY2024: $7.1M
Diluted EPS-$2.63TTM
'19'20'21'22'23'24'25
FY2025: $-2.34

Dividend

No dividend

Capital Allocation

R&D Spend$18M
Capex Intensity14.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.